EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predicting time to relapse in acute myeloid leukemia through stochastic modeling of minimal residual disease based on clonality data

Khanh N Dinh, Roman Jaksik, Seth J Corey, Marek Kimmel

Computational and Systems Oncology · 2021

DOI: 10.1002/cso2.1026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Computational and Systems Oncology, 2021. Verfasst von Khanh N Dinh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Irving Institute of Cancer Dynamics, Columbia University, New York, NY, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Event‐free and overall survival remain poor for patients with acute myeloid leukemia. Chemoresistant clones contributing to relapse arise from minimal residual disease (MRD) or newly acquired mutations. However, the dynamics of clones comprising MRD is poorly understood. We developed a predictive stochastic model, based on a multitype age‐dependent Markov branching process, to describe how random events in MRD contribute to the heterogeneity in treatment response. We employed training and validation sets of patients who underwent whole‐genome sequencing and for whom mutant clone frequencies at diagnosis and relapse were available. The disease evolution and treatment outcome are subject to stochastic fluctuations. Estimates of malignant clone growth rates, obtained by model fitting, are consistent with published data. Using the estimates from the training set, we developed a function linking MRD and time of relapse with MRD inferred from the model fits to clone frequencies and other data. An independent validation set confirmed our model. In a third dataset, we fitted the model to data at diagnosis and remission and predicted the time to relapse. As a conclusion, given bone marrow genome at diagnosis and MRD at or past remission, the model can predict time to relapse and help guide treatment decisions to mitigate relapse.

Schlagwörter

Stichwörter der Autor:innen

acute myeloid leukemiaclonal evolutionminimal residual disease

Autor:innen und Institutionen

  • Irving Institute of Cancer Dynamics, Columbia University, New York, NY, USA.
  • Department of Systems Biology and Engineering, Silesian University of Technology, Gliwice, Poland.
  • Departments of Pediatric Hematology/Oncology and Stem Cell Transplantation and Cancer Biology, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Statistics, Rice University, Houston, TX, USA.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Dinh, K. N., Jaksik, R., Corey, S. J., & Kimmel, M. (2021). Predicting time to relapse in acute myeloid leukemia through stochastic modeling of minimal residual disease based on clonality data. Computational and Systems Oncology. https://doi.org/10.1002/cso2.1026

Vancouver

Dinh KN, Jaksik R, Corey SJ, Kimmel M. Predicting time to relapse in acute myeloid leukemia through stochastic modeling of minimal residual disease based on clonality data. Computational and Systems Oncology. 2021. doi:10.1002/cso2.1026

BibTeX
@article{Dinh2021,
  author = {Dinh, Khanh N and Jaksik, Roman and Corey, Seth J and Kimmel, Marek},
  title = {Predicting time to relapse in acute myeloid leukemia through stochastic modeling of minimal residual disease based on clonality data},
  journal = {Computational and Systems Oncology},
  year = {2021},
  doi = {10.1002/cso2.1026}
}
Kostenlos starten →